OncoImmune, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
OncoImmune, Inc. - overview
Established
2000
Location
Rockville, MD, US
Primary Industry
Pharmaceuticals
About
Founded in 2000 and based in Maryland, US, OncoImmune, Inc. , the developer of CD24Fc, a prophylactic treatment for Graft versus Host Disease (GvHD) of leukemia patients that undergoes hematopoietic stem cell transplantation. The company's pharmaceutical also provides treatment for cancer and autoimmune diseases.
Current Investors
3E Bioventures Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.oncoimmune.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.